← Back to Analyst Consensus 
TVTX Buy
Travere Therapeutics, Inc.
Current Price —
Implied Upside —
Analysts 21
30-Day Momentum
▲ 0 upgrades / ▼ 0 downgrades / 0 reiterations from 0 firms
Rating Timeline
| Date ▼ | Firm | Action | From → To Rating | Price Target | Firm Rating |
|---|---|---|---|---|---|
| Sep 24, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Sep 22, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Sep 22, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Aug 10, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| Aug 6, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Aug 6, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Aug 5, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| Aug 5, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Aug 5, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| Aug 5, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jul 30, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Jun 25, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Jun 22, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Jun 18, 2026 | Evercore ISI Group | maintain | Outperform → Outperform | — | 58% |
| Jun 15, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Jun 12, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| Jun 3, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Jun 3, 2026 | Wedbush | reiterate | Outperform → Outperform | — | 58% |
| Jun 2, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| May 6, 2026 | Wells Fargo | maintain | Overweight → Overweight | — | 54% |
| May 5, 2026 | TD Cowen | maintain | Buy → Buy | — | 54% |
| May 5, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| May 5, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| May 5, 2026 | HC Wainwright & Co. | maintain | Buy → Buy | — | 44% |
| Apr 24, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Apr 14, 2026 | Citigroup | maintain | Buy → Buy | — | 54% |
| Apr 14, 2026 | Canaccord Genuity | maintain | Buy → Buy | — | 48% |
| Apr 14, 2026 | Wedbush | maintain | Outperform → Outperform | — | 58% |
| Apr 14, 2026 | Guggenheim | maintain | Buy → Buy | — | 52% |
| Apr 14, 2026 | HC Wainwright & Co. | reiterate | Buy → Buy | — | 44% |
| Mar 25, 2026 | JP Morgan | maintain | Overweight → Overweight | — | 54% |
| Feb 6, 2026 | Piper Sandler | maintain | Neutral → Neutral | $38 | 54% |
| Nov 28, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $47 | 44% |
| Nov 4, 2025 | Piper Sandler | maintain | Neutral → Neutral | $35 | 54% |
| Oct 31, 2025 | TD Cowen | maintain | Buy → Buy | $40 | 54% |
| Sep 19, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $47 | 44% |
| Sep 12, 2025 | Stifel | maintain | Hold → Hold | $25 | 53% |
| Sep 11, 2025 | Wells Fargo | maintain | Overweight → Overweight | $35 | 54% |
| Sep 10, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $47 | 44% |
| Sep 3, 2025 | HC Wainwright & Co. | reiterate | Buy → Buy | $47 | 44% |
| Aug 28, 2025 | HC Wainwright & Co. | maintain | Buy → Buy | $47 | 44% |
| Aug 7, 2025 | Scotiabank | maintain | Sector Outperform → Sector Outperform | $31 | 55% |
| Aug 7, 2025 | Wedbush | maintain | Outperform → Outperform | $32 | 58% |
| Jun 11, 2025 | Citigroup | maintain | Buy → Buy | $32 | 54% |
| May 16, 2025 | Wedbush | reiterate | Outperform → Outperform | $30 | 58% |
| May 2, 2025 | Wedbush | reiterate | Outperform → Outperform | $30 | 58% |
| May 2, 2025 | Stifel | maintain | Hold → Hold | $23 | 53% |
| Apr 23, 2025 | Cantor Fitzgerald | reiterate | Overweight → Overweight | $0 | 50% |
| Apr 14, 2025 | Guggenheim | reiterate | Buy → Buy | $47 | 52% |
| Apr 10, 2025 | Canaccord Genuity | maintain | Buy → Buy | $47 | 48% |
Price Target Trend
May 4, 2026 Latest: $75.21 Oct 25, 2026
EPS Estimates
+1q $1.07
Lo: $0.65 Hi: $2.03
8 analysts ▲4
0q $0.49
Lo: $-0.57 Hi: $1.16
8 analysts ▲1
+1y $5.70
Lo: $3.50 Hi: $6.95
8 analysts ▲4
0y $1.67
Lo: $0.96 Hi: $2.95
8 analysts ▲1
Cross-Platform Signals
No cross-platform signals in the last 90 days